Becotatug Vedotin (MRG003) in Combination With PD-1 Inhibitor Versus PD-1 Inhibitor for the Treatment of EGFR-positive, CPS≥1 Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

NCT07524452 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

430

Enrollment

OTHER

Sponsor class

Conditions

Locally Advanced Head and Neck Squamous Cell Carcinoma

Interventions

DRUG: Neoadjuvant and Adjuvant Becotatug Vedotin
DRUG: Neoadjuvant and Adjuvant Immunotherapy
PROCEDURE: Surgery
RADIATION: Adjuvant Radiotherapy
DRUG: Adjuvant Cisplatin

Sponsor

Ming-Yuan Chen